No Data
No Data
Express News | Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of Lyl314 for the Treatment of Large B-Cell Lymphoma at the International Conference on Malignant Lymphoma (Icml) 2025
Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
H.C. Wainwright Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $1
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Lyell Immunopharma Analyst Ratings
Express News | Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma